NCT04670055

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Clinical Trial for the Safety and Efficacy of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for relapsed BCMA+ multiple myeloma, the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 50 patients will be enrolled for this trial. Primary objective is to explore the safety, main consideration is dose-related safety.

Conditions

• Relapse Multiple Myeloma
• Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	BCMA Targeted CAR T-cells	Each subject receive BCMA Targeted CAR T-cells by intravenous infusion

Timeline

• Start date: 2021-01-01
• Primary completion: 2024-01-01
• Completion: 2027-01-01
• First posted: 2020-12-17
• Last updated: 2020-12-17

Locations

1 site across 1 country: China